Five things for pharma marketers to know: Friday, April 20, 2018

Allergan reverses course on Shire deal; Merck seeks partners for cancer, immune system drugs; J&J diversified vision portfolio and it's paying off.

P&G: healthcare acquisition helps us stay on top of consumer 'megatrends'

Procter & Gamble said its $4.2 billion acquisition of German firm Merck's consumer health division was about allowing it to respond to the changing demands ...

Private-equity funds dominate marcomms M&A

Nearly a quarter (22%) of all marcomms M&A deals involved private-equity funds — double the 11% seen in the last two quarters of 2017.

PBMs, drugmakers face off over copay accumulators

PBMs, drugmakers face off over copay accumulators

As with most drug pricing battles, patients yet again are caught in the crossfire.

The MM&M buyer's guide to boutique consulting services

The MM&M buyer's guide to boutique consulting services

You've seen what the biggies can do. What about the smaller end of the spectrum? MM&M's second buyer's guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don'ts of hiring boutique firms.

Can the healthcare industry really expect to drive patient engagement?

Can the healthcare industry really expect to drive patient engagement?

Increasing patient engagement as a tool for improving care and outcomes has been a tough code to crack for the healthcare industry.

Five things for pharma marketers to know: Thursday, April 19, 2018

Five things for pharma marketers to know: Thursday, April 19, 2018

Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.

Read and Scott: 'We don't believe break-up of WPP makes sense'

Read and Scott: 'We don't believe break-up of WPP makes sense'

WPP's joint chief operating officers Mark Read and Andrew Scott have said they do not believe a break-up of the ad group makes sense.

Ogilvy CEO John Seifert on Martin Sorrell's exit: 'The show must go on'

Ogilvy CEO John Seifert on Martin Sorrell's exit: 'The show must go on'

Seifert said feedback from clients has been positive.

Five things for pharma marketers to know: Wednesday, April 18, 2018

Five things for pharma marketers to know: Wednesday, April 18, 2018

Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.

Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'

Omnicom Health's CEO on agency consolidation and why Japan's healthcare market is a 'bellwether'

The healthcare marketing group made another major acquisition in the country last month.

Omnicom beats estimates in Q1, but sees slight dip in North America

Omnicom beats estimates in Q1, but sees slight dip in North America

Omnicom's healthcare revenue was up 2.7% in Q1

Five things for pharma marketers to know: Tuesday, April 18, 2018

Five things for pharma marketers to know: Tuesday, April 18, 2018

J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.

Sorrell on Sorrell: ex-WPP chief in his own words

Sorrell on Sorrell: ex-WPP chief in his own words

Campaign looks back at some of Sir Martin Sorrell's musings, barbs and pearls of wisdom in recent times.

Spectrum brings on biopharma, biotech, creative execs

Spectrum brings on biopharma, biotech, creative execs

The firm hired five senior staff in the past month.

Five things for pharma marketers to know: Monday, April 16, 2018

Five things for pharma marketers to know: Monday, April 16, 2018

Shire sale of oncology business makes it more affordable for Takeda; FDA reverses course on Alkermes depression drug; Sorrell out as WPP CEO.

Forensic, focused, cantankerous: nine reflections on Sorrell and his style

Forensic, focused, cantankerous: nine reflections on Sorrell and his style

As Sir Martin clears his desk, PRWeek has collected nine thoughts from the worlds of PR, journalism and agency life on the man, his skills, his temperament, and his future.

Sorrell exit could spell the end for WPP, analysts say

Sorrell exit could spell the end for WPP, analysts say

Martin Sorrell's resignation as chief executive of WPP could lead to a breakup of the company and spark other major changes.

Sorrell departs WPP: how an outsider shaped the global ad industry

Sorrell departs WPP: how an outsider shaped the global ad industry

John Tylee examines how a man who never ran an agency rose to become such a dominant force.

Sorrell quits as WPP chief executive

Sorrell quits as WPP chief executive

Martin Sorrell has stood down as chief executive of WPP, the company has announced.

WPP board to meet as Sorrell probe nears conclusion

WPP board to meet as Sorrell probe nears conclusion

WPP's board of directors is set to meet as it awaits the outcome of an investigation into the personal conduct of CEO Martin Sorrell.